Market Closed - OTC Markets 01:00:58 2024-04-25 pm EDT 5-day change 1st Jan Change
1.3 USD -2.99% Intraday chart for SeqLL Inc. -35.00% -68.52%

This article is reserved for members

Already a member?

Log In

Not a member ?

Free registration
SeqLL Inc. Reports Earnings Results for the Full Year Ended December 31, 2023 CI
SeqLL Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023 CI
SeqLL Inc.(NasdaqCM:SQL) dropped from S&P TMI Index CI
SeqLL Inc.(OTCPK:SEQL) dropped from NASDAQ Composite Index CI
SeqLL Inc. Announces Cancelation of Special Cash Dividend CI
Top Premarket Gainers MT
Top Premarket Decliners MT
SeqLL Announces 1-for-40 Reverse Stock Split MT
SeqLL Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023 CI
SeqLL Inc. to Appoint Prateek Gattani as Chairman of the Board CI
Lyneer Investments, LLC entered into a definitive merger agreement to acquire SeqLL Inc. from a group of shareholders for approximately $140 million in a reverse merger transaction. CI
Top Premarket Decliners MT
SeqLL Inc. Reports Earnings Results for the First Quarter Ended March 31, 2023 CI
Earnings Flash (SQL) SEQLL Reports Q4 Revenue $78,659 MT
SeqLL Prices $1.8 Million Registered Direct Offering; Shares Fall MT
Top Premarket Gainers MT
Top Midday Gainers MT
SeqLL Signs R&D Contract With FBI to Create Forensic Body Fluid Test; Shares Soar Over 200% Midday MT
SeqLL Shares Jump 300%, Hitting 52-Week High, on FBI Contract DJ
SeqLL in Cooperative Research, Development Agreement With FBI DJ
SeqLL Inc. Announces Cooperative Research and Development Agreement with the Federal Bureau of Investigation CI
Brian Paras Joins SeqLL as Chief Business Officer CI
SeqLL Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2022 CI
SeqLL Says Liquid Biopsy Method Helps in Early Cancer Detection MT
SeqLL Inc. Announces Peer-Reviewed Publication of Novel Single-Molecule Liquid Biopsy Method in Nature Biotechnology CI
Chart SeqLL Inc.
More charts
SeqLL Inc. (SeqLL) is a life sciences instrumentation and research services company that is engaged in the development of scientific assets and intellectual property across multiple omics fields. The Company is engaged in the design, development and manufacturing of genetic analysis technologies. It leverages its True Single Molecule Sequencing (tSMS) technology, which enables researchers and clinicians to contribute advancements to scientific research and development. Its tSMS platform offers a single molecule solution for deoxyribonucleic acid (DNA) and ribonucleic acid (RNA) sequencing by performing detection of nucleic acids without the need for complex sample manipulation. Researchers using its platform can analyze billions of single molecules in a single experiment and generate reproducible data. Its single molecule platform combines a fluorescence-based optical detection apparatus with a precision microfluidics and thermal control system to perform sequencing-by-synthesis.
More about the company